If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
To address specific nutritional needs of individual patients, several providers of IDPN therapy developed formulations that take clinical variables into account in order to best fit the patient's individual needs and condition. Specific formulations address distinct differences between nutritional needs of those patients who exhibit protein malnutrition and those patients who exhibit calorie malnutrition. Nutrition Clinical nutrition
Researchers in the field have developed approaches to produce living organs that are constructed with the appropriate biological and mechanical properties. 3D bioprinting is based on three main approaches: biomimicry, autonomous self-assembly and mini-tissue building blocks. The first approach of bioprinting is called biomimicry. The main goal of this approach is to create fabricated structures that are identical to the natural structure that are found in the tissues and organs in the human body. Biomimicry requires duplication of the shape, framework, and the microenvironment of the organs and tissues. The application of biomimicry in bioprinting involves creating both identical cellular and extracellular parts of organs. For this approach to be successful, the tissues must be replicated on a micro scale. Therefore, it is necessary to understand the microenvironment, the nature of the biological forces in this microenvironment, the precise organization of functional and supporting cell types, solubility factors, and the composition of extracellular matrix.
Naturally occurring niobium (41Nb) is composed of one stable isotope (93Nb). The most stable radioisotope is 92Nb with a half-life of 34.7 million years, followed by 94Nb at a half-life of 20,400 years and 91Nb at 680 years. Other radioisotopes that have been synthesized range from 82Nb to 110Nb; these have half-lives that are less than two hours, except 95Nb (34.991 days), 96Nb (23.35 hours) and 90Nb (14.60 hours). The most stable of the meta states is 93mNb with excitation energy 31 keV and a 16.1 year half-life; this is produced in the decay of 93Zr. The primary decay mode before stable 93Nb is electron capture to zirconium isotopes and the primary mode after is beta emission, with delayed neutron emission starting at 104Nb, leading to molybdenum isotopes. Only 95Nb, along with 97Nb (72 minutes) and heavier isotopes (seconds) are fission products in significant quantity, as the other isotopes are shadowed by stable or very long-lived (93) isotopes of the preceding element zirconium from the usual mode of production through beta decay of neutron-rich fission fragments. 95Nb is the decay product of 95Zr (64 days), so disappearance of 95Nb in used nuclear fuel is slower than would be expected from its own 35-day half-life alone.
Sources: en.wikipedia.org
Shrewsbury, UK: Airlife Publishing Ltd., 1992. ISBN 1-85310-212-1. Jerram, Michael F. P-51 Mustang. Yeovil, UK: Winchmore Publishing Services Ltd., 1984, ISBN 0-85429-423-6. Johnsen, Frederick A. Bell P-39/P-63 Airacobra & Kingcobra. St. Paul, Minnesota: Voyageur Press, 1998. ISBN 1-58007-010-8. Johnsen, Frederick A. North American P-51 Mustang. North Branch, Minnesota: Specialty Press Publishers and Wholesalers, 1996. ISBN 0-933424-68-X. Kaplan, Philip. Fly Navy: Naval Aviators and Carrier Aviation: A History. New York: Michael Friedman Publishing Group Incorporated, 2001. ISBN 1-58663-189-6. Kinzey, Bert. P-51 Mustang in Detail & Scale: Part 1; Prototype through P-51C. Carrollton, Texas: Detail & Scale Inc., 1996. ISBN 1-888974-02-8. Kinzey, Bert. P-51 Mustang in Detail & Scale: Part 2; P-51D thu P-82H. Carrollton, Texas: Detail & Scale Inc., 1997. ISBN 1-888974-03-6 Knaack, Marcelle Size. Encyclopedia of U.S. Air Force Aircraft and Missile Systems: Volume 1 Post-World War II Fighters 1945–1973. Washington, D.C.: Office of Air Force History, 1978. ISBN 0-912799-59-5. Lawrence, Joseph (1945). The Observer's Book Of Airplanes. London and New York: Frederick Warne & Co. Lednicer, David A. and Ian J. Gilchrist. "A Retrospective: Computational Aerodynamic Analysis Methods Applied to the P-51 Mustang." AIAA paper 91-3288, September 1991. Lednicer, David A. "Technical Note: A CFD Evaluation of Three Prominent World War II Fighter Aircraft." Aeronautical Journal, Royal Aeronautical Society, June/July 1995. Lednicer, David A.
All the Rh(III) halides are known. Synthesis of many rhodium complexes begin with RhCl3·3H2O, the hydrated trichloride, but RhCl3, the anhydrous form, is largely inert. Other rhodium(III) chlorides include sodium hexachlororhodate, Na3RhCl6, and pentaamminechlororhodium dichloride, [Rh(NH3)5Cl]Cl2. They are used in the recycling and purification of this very expensive metal. Heating a methanolic solution of hydrated rhodium trichloride with sodium acetate gives the blue-green rhodium(II) acetate, Rh2(O2CCH3)4, which features a Rh–Rh bond. This complex and related rhodium(II) trifluoroacetate have attracted attention as catalysts for cyclopropanation reactions. Heating treated with triphenylphosphine in ethanol, hydrated rhodium trichloride converts to RhCl(P(C6H5)3)3. This square planar complex, which is known as Wilkinson's catalyst, is a common and early example of a well-defined homogeneous catalyst for hydrogenation of alkenes.
Noni tea Oksusu cha, traditional roasted corn tea found in Korea Olive leaf tea Oregano tea Osmanthus tea, dried flowers of the sweet olive tree, are used alone or blended with tea leaves in China. Pandan tea Patchouli tea Pennyroyal leaf, an abortifacient Pine needle tea, or tallstrunt, made from needles of pine trees Qishr, Yemeni drink with coffee husks and ginger Red clover tea Red raspberry leaf Rosa × damascena tea, in the Middle East. Roasted wheat, used in Postum, a coffee substitute Rooibos (red bush), a reddish plant used to make an infusion and grown in South Africa. In the US it is sometimes called red tea. It has many of the antioxidant characteristics of green tea, but because it does not come from tea leaves, it has no caffeine. Rose hip (often blended with hibiscus) Roselle petals (species of hibiscus; known by other names including bissau and dah), consumed in the Sahel and elsewhere Rosemary Sabah snake grass is used as a traditional herbal tea infusion in Southeast Asia. Sagebrush, California sagebrush Sage Sakurayu, Japanese herbal tea made with pickled cherry blossom petals Sassafras roots were steeped to make tea, a practice which was common among Native Americans. They were also used in the flavoring of root beer until being banned by the FDA.
Sources: en.wikipedia.org
=== Location === Tarlov cysts are most commonly located in the S1 to S4/S5 region of the spinal canal, but can be found along any region of the spine. Tarlov cysts typically form on the extradural portions of the sacral nerve roots, most often near the dorsal root ganglion of the dorsal (sensory) nerve roots. They arise within the perineural space, between the endoneurium and perineurium. Occasionally, these cysts are observed in the lumbar and thoracic spine. The cysts are often multiple, extending around the circumference of the nerve, and can enlarge over time to compress neighboring nerve roots, to cause bone erosion. The cysts may also form on the anterior (front) side of the sacrum and have been known to extend into the pelvic cavity. These cysts, though rare, can be found to grow large - over 3–4 centimetres (1.2–1.6 in) in size, often causing severe pelvic pain from compression on the cyst itself as well as adjoining nerves.
==== Other drugs ==== Alpiropride (Revistel, Rivistel, Rivestel) – dopamine D2 receptor antagonist – migraine Dimetotiazine (Banistyl, Normelin) – non-selective monoamine receptor modulator – migraine Flumedroxone acetate (Demigran, Leomigran) – progestogen (progesterone receptor agonist) – migraine Iprazochrome (Divascan) – serotonin receptor antagonist – migraine Lasmiditan (COL-144; LY-573144; Rayvow; Reyvow) – serotonin 5-HT1F receptor agonist – migraine [141] Lomerizine (DE-090; KB-2796; Migsis) – non-selective monoamine receptor modulator, other actions – migraine [142] Onabotulinum toxin A (BoNTA; Botox; GSK-1358820; OnabotA X; Vistabel; Vistabex) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [143] Oxetorone (Nocertone, Oxedix) – non-selective monoamine receptor modulator – migraine Topiramate (Epitomax; KW-6485; MCN-4853; RWJ-17021; Topamax; Topimax; Topina) – various actions – migraine [144] Topiramate oral (Eprontia; ET-101) – various actions – migraine [145] Topiramate extended-release (SPN-538; TPM XR; Trokendi XR; Trokesa) – various actions – migraine [146] Valproate semisodium (Depakote; Divalproex; Divalproex sodium; Epival; LA40220) – various actions – migraine [147]
In the first half of the 16th century Paracelsus proposed a theory of mineral formation as an analogy to fruit-bearing plants. In 1550 Gerolamo Cardano made an early attempt to explain the shape of crystals as the result of a close packing of spheres. In 1591 Thomas Harriot studied the close packing of cannonballs (spheres). In 1597 Andreas Libavius recognized the geometrical characteristics of crystals and identified salts from their crystal shape.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.